{"slug":"adipotide","seoKey":"adipotide","displayName":"Adipotide","codes":["Prohibitin-TP01","FTPP","HKPao"],"synonyms":["Prohibitin-TP01","prohibitin targeting peptide 1","FTPP","fat targeted proapoptotic peptide","proapoptotic peptide (PP)","ATS-(KLAKLAK)2","prohibitin-targeting peptidomimetic"],"legalClass":"investigational","identifiers":{"cas":"859216-15-2","pubchemCid":163360068,"inchikey":"GZESIPHLGJDZRG-VCWDIOOSSA-N","formula":"C111H206N36O28S2","molecularWeight":2557.2,"sequence":"CKGGRAKDC-GG-D(KLAKLAK)2"},"approvals":[{"market":"US","status":"investigational","note":"Not approved and never has been. Queries on 2026-09-12 returned no entry in the drug approval records, no product labelling and no enforcement record; a control query for an approved medicine on the same endpoints returned results, so the endpoints were working. An investigational new drug application was filed and a single first-in-man trial opened in 2012. Unlike several other research peptides, the substance was never even nominated as a bulk substance for compounding, so it does not appear in the corresponding safety-risk category either.","source":"https://api.fda.gov/drug/drugsfda.json?search=adipotide"},{"market":"EU","status":"not_approved","note":"No authorised medicine, no assessment report and no withdrawn-application record. The complete medicines list was searched on 2026-09-12 for the substance name and for the target protein with no match, while control terms in the same file were found. The interactive website search returned HTTP 401 on that date, so the negative finding rests on the medicines list rather than on the site search.","source":"https://www.ema.europa.eu/en/medicines"},{"market":"DE","status":"not_approved","note":"Not an authorised medicine. A substance with a medicinal purpose may not be placed on the market without an authorisation, and there is neither a central European authorisation nor a national finished medicine. Not listed in annexes I, II or III of the narcotics act, the full text having been searched on 2026-09-12 with no match.","source":"https://www.gesetze-im-internet.de/amg_1976/__21.html"},{"market":"UK","status":"not_approved","note":"No authorised medicine and no product record. A direct query of the products register was not evaluable on 2026-09-12, because results load by script and the interface endpoints answered with an error or an empty body. The negative finding therefore rests on the absence of any authorisation worldwide and on the fact that development never went beyond a single terminated phase 1 trial.","source":"https://products.mhra.gov.uk/search/?search=adipotide"},{"market":"AU","status":"not_approved","note":"Not named in the 2026 Poisons Standard; the full text was searched on 2026-09-12 for the substance name, the target protein and the effector sequence with no match, while control terms in the same document were found. The absence of a listing does not make the substance freely available, since an injectable unlisted substance with a therapeutic purpose is not permitted goods without a register entry. A full-text query of the register of therapeutic goods was not possible on that date, the regulator site being unreachable.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No authorised medicine. The drug product database returned an empty result for the active ingredient on 2026-09-12, while a control query on the same endpoint returned several entries, so the negative finding is verified.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=adipotide"},{"market":"CH","status":"not_approved","note":"No authorisation. Both regulator registers, the human medicines authorisations and the package index, were searched on 2026-09-12 for the substance name and the target protein with no match, while control terms in the same files returned numerous entries.","source":"https://www.swissmedic.ch/"}],"devStage":"discontinued","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT01262664","name":"A first-in-man, phase 1 evaluation of a single cycle of prohibitin targeting peptide 1","phase":"Phase 1","n":4,"status":"TERMINATED"}],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/163360068"],"lastVerified":"2026-09-12","version":"1.0","published":true,"locale":"en","title":"Adipotide: what the studies show, status and safety","summary":"Adipotide is not a metabolic drug but a cell-killing conjugate: an address tag that finds a protein on blood vessels in white fat, joined to a piece that destroys mitochondria. In monkeys it lowered weight and fat, and injured the kidneys in every dose group tested. Its only human trial closed after four patients, and no country has approved it.","updated":"2026-09-12","url":"https://mypep.app/peptides/adipotide"}